Page 48 - AN-3-4

Advanced Neurology Anticoagulants as neuroprotective therapeutics

plaques and beta-amyloid accumulation in a mouse model of 2005;36(12):2637-2641.
Alzheimer’s disease. J Neurosci. 2004;24(17):4181-4186.
doi: 10.1161/01.STR.0000189721.31432.26
doi: 10.1523/JNEUROSCI.0550-04.2004
113. Ryu JK, Rafalski VA, Meyer-Franke A, et al. Fibrin-targeting
103. Timmer NM, Van Dijk L, Van der Zee CE, Kiliaan A, De Waal immunotherapy protects against neuroinflammation and
RM, Verbeek MM. Enoxaparin treatment administered at neurodegeneration. Nat Immunol. 2018;19(11):1212-1223.
both early and late stages of amyloid β deposition improves doi: 10.1038/s41590-018-0232-x
cognition of APPswe/PS1dE9 mice with differential effects
on brain Aβ levels. Neurobiol Dis. 2010;40(1):340-347. 114. Silva LM, Doyle AD, Greenwell-Wild T, et al. Fibrin is a
critical regulator of neutrophil effector function at the oral
doi: 10.1016/j.nbd.2010.06.008
mucosal barrier. Science. 2021;374(6575):1575.
104. Friberg L, Rosenqvist M. Less dementia with oral doi: 10.1126/science.abl5450
anticoagulation in atrial fibrillation. Eur Heart J.
2018;39(6):453-460. 115. Salminen A, Kauppinen A, Kaarniranta K. Hypoxia/
ischemia activate processing of amyloid precursor protein:
doi: 10.1093/eurheartj/ehx579
Impact of vascular dysfunction in the pathogenesis of
105. Tripathy D, Sanchez A, Yin X, Luo J, Martinez J, Grammas P. Alzheimer’s disease. J Neurochem. 2017;140(4):536-549.
Thrombin, a mediator of cerebrovascular inflammation in doi: 10.1111/jnc.13932
AD and hypoxia. Front Aging Neurosci. 2013;5:19.
116. Ahn HJ, Glickman JF, Poon KL, et al. A novel Aβ-fibrinogen
doi: 10.3389/fnagi.2013.00019
interaction inhibitor rescues altered thrombosis and
106. Kantor AB, Akassoglou K, Stavenhagen JB. Fibrin-targeting cognitive decline in Alzheimer’s disease mice. J Exp Med.
immunotherapy for dementia. J Prev Alzheimers Dis. 2014;211(6):1049-1062.
2023;4(10):647-660.
doi: 10.1084/jem.20131751
doi: 10.14283/jpad.2023.105
117. Roher AE, Debbins JP, Malek-Ahmadi M, et al. Cerebral
107. Coughlin SR. Protease-activated receptors in hemostasis, blood flow in Alzheimer’s disease. Vasc Health Risk Manag.
thrombosis and vascular biology. J Thromb Haemost. 2012;8:599-611.
2005;3(8):1800-1814.
doi: 10.2147/VHRM.S34874
doi: 10.1111/j.1538-7836.2005.01377.x
118. Asslani I, Habeck C, Scarmeas N, Borodovac A, Brown TR,
108. Cajamarca SA, Norris EH, Van der Weerd L, Strickland S, Stern Y. Multivariate and univariate analysis of continuous
Ahn HJ. Cerebral amyloid angiopathy-linked β-amyloid arterial spin labeling perfusion MRI in Alzheimer’s disease.
mutations promote cerebral fibrin deposits via increased J Cereb Blood Flow Metab. 2008;28(4):725-736.
binding affinity to fibrinogen. Proc Natl Acad Sci USA. doi: 10.1038/sj.jcbfm.9600570
2020;117(25):14482-14492.
119. Zhang H, Wang Y, Lyu D, et al. Cerebral blood flow in mild
doi: 10.1073/pnas.1921327117
cognitive impairment and Alzheimer’s disease: A systematic
109. Wen T, Zhang Z. Cellular mechanisms of fibrin (ogen): review and meta-analysis. Aging Res Rev. 2021;71:101450.
Insight from neurodegenerative diseases. Front Neurosci.
2023;17:1197094. doi: 10.1016/j.arr.2021.101450
120. Müller S, Preische O, Sohrabi HR, et al. Relationship between
doi: 10.3389/fnins.2023.1197094
physical activity, cognition, and Alzheimer pathology
110. Choi SH, Lee DY, Kim SU, Jin BK. Thrombin-induced in autosomal dominant Alzheimer’s disease. Alzheimers
oxidative stress contributes to the death of hippocampal Dement. 2018;14(11):1427-1437.
neurons in vivo: Role of microglial NADPH oxidase.
J Neurosci. 2005;25(10):4082-4090. doi: 10.1016/j.jalz.2018.06.3059
121. Montagne A, Nation DA, Sagare AP, et al. APOE4 leads
doi: 10.1523/JNEUROSCI.4306-04.2005
to blood-brain barrier dysfunction predicting cognitive
111. Bihaqi SW, Rao HV, Sen A, Grammas P. Dabigatran reduces decline. Nature. 2020;581(7806):71-76.
thrombin-induced neuroinflammation and AD markers in
vitro: Therapeutic relevance for Alzheimer’s disease. Cerebr doi: 10.1038/s41586-020-2247-3
Circu-Cogn Behav. 2021;2:100014. 122. Marangoni MN, Braun D, Situ A, et al. Differential effects
on glial activation by a direct versus an indirect thrombin
doi: 10.1016/j.cccb.2021.100014
inhibitor. J Neuroimmunol. 2016;297:159-168.
112. Van Oijen M, Witteman JC, Hofman A, Koudstaal PJ,
Breteler MMB. Fibrinogen is associated with an increased doi: 10.1016/j.jneuroim.2016.05.018
risk of Alzheimer disease and vascular dementia. Stroke. 123. Iannucci J, Johnson SL, Majchrazak M, et al. Short-term

Volume 3 Issue 4 (2024) 30 doi: 10.36922/an.3799